Roger Edgley Comments on M3 Inc.

M3, Inc. ( TSE:2413 ) is another Japanese company that has flourished by helping pharmaceutical companies to more effectively deliver drug information to doctors online. Leveraging its doctor network and technology platform, M3 entered the contract research organization (CRO) space a few years ago and has become one of the top three CRO companies in Japan. The company's platform automates and optimizes portions of the clinical trial process to help bring drugs to market faster and cheaper.

From Roger Edgley's 1st Quarter 2017 Wasatch International Growh Fund Shareholder Letter .

• DPZ 15-Year Financial Data
• The intrinsic value of DPZ
• Peter Lynch Chart of DPZ

Premium Members

This article first appeared on GuruFocus .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.